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Abstract
Background Cachexia is a multiorganic syndrome associated
with cancer, characterized by body weight loss, muscle and
adipose tissue wasting and inflammation.
Methods The aim of this investigation was to examine the
effect of the soluble receptor antagonist of myostatin
(sActRIIB) in cachectic tumor-bearing animals analyzing
changes in muscle proteolysis and in quality of life.
Results Administration of sActRIIB resulted in an improve-
ment in body and muscle weights. Administration of the
soluble receptor antagonist of myostatin also resulted in an
improvement in the muscle force.
Conclusions These results suggest that blocking myostatin
pathway could be a promising therapeutic strategy for the
treatment of cancer cachexia.
Keywords Myostatin . Cancer cachexia . Skeletal muscle .
Physical activity . Muscle force . Ubiquitin
1 Introduction
Cachexia is a multiorganic syndrome associated with
cancer, characterized by body weight loss (at least 5%),
muscle and adipose tissue wasting and inflammation, being
often associated with anorexia [1]. The abnormalities
associated with cachexia include alterations in carbohydrate,
lipid, and protein metabolism [1–3]. In advanced malignant
diseases, cachexia appears to be one of the most common
systemic manifestations. The presence of cachexia always
implies a poor prognosis, having a great impact on the
patients' quality of life and survival [4]. Several important
molecular mechanisms have been shown to be involved in
the increased muscle catabolism observed in cancer-induced
cachexia, such as greater ubiquitin–proteasome-dependent
proteolysis, apoptosis, and activation of uncoupling
proteins [2, 5–7]. Interaction of these mechanisms leads
to muscle-mass loss by promoting protein and DNA
breakdown and energy inefficiency.
Myostatin, also known as GDF-8 (growth and differen-
tiation factor-8), is a member of the TGF-b superfamily of
secreted growth factors and is a negative regulator of
skeletal muscle development [8–10]. During embryogenesis,
myostatin expression is restricted to developing skeletal
muscles, but the protein is still expressed and secreted by
skeletal muscles in adulthood [11, 12]. Mice and cattle with
genetic deficiencies in myostatin exhibit dramatic increases
in skeletal muscle mass, therefore supporting the role of
myostatin in suppressing muscle growth [13]. Myostatin acts
systemically (it is produced in muscle, adipose tissue, and
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heart [14] and released to the circulation) and binds to
cell-surface receptors causing muscle loss. The myostatin
protein circulates in the blood in a latent form as a full-length
precursor that is cleaved into an amino-terminal pro-peptide
and a carboxy-terminal mature region, which is the active
form of the molecule. Once activated, myostatin has high
affinity for the activin IIB receptor (Acvr2b, also known
as ActRIIB) and weak affinity for Acvr2a (also known
as ActRII and ActRIIA), both of which, like other
receptors for TGF-β family members, bind multiple
ligands [15, 16]. Liu et al. used a myostatin anti-sense
RNA and found that the oligonucleotides could suppress
myostatin expression in vivo resulting in an increase in
muscle growth both in healthy and cachectic mice [17].
Interestingly, the effect of the RNA oligonucleotides was a
significant upregulation of MyoD expression, therefore
reinforcing the role of this transcription factor in muscle
wasting [18, 19]. Although the use of the deacetylase
inhibitors to increase the levels of follistatin (an antagonist
of myostatin) has not lead to any positive results in the
treatment of cachexia in experimental animals [20, 21], the
use of the activin receptor extracellular domain/Fc fusion
protein (ACVR2B-Fc) has been shown to be effective in
the treatment of muscle wasting in tumor-bearing animals
[21]. Finally, and very recently, Zhou et al. have shown
that the administration of a high-affinity activin type II
receptor leads to prolonged survival in tumor-bearing mice
[22]. This receptor regulates the expression of target genes
through to a TGFβ pathway. Myostatin signaling acts
through this receptor in skeletal muscle by setting in
motion an intracellular cascade of events involving SMAD
proteins, p38 MAPK, ERK1/2, PI3-K/AKT, and Wnt
pathways [23–26].
Bearing all this in mind, the objective of the present
investigation was to analyze in animals bearing the Lewis
lung carcinoma the effects of ActRIIB antagonism on both
muscle weights and force.
2 Material and methods
2.1 Animals
C57Bl/6 male mice (Criffa, Barcelona, Spain), of about
20 g were used in the different experiments. The animals
were maintained at 22±2°C with a regular light–dark cycle
(light on from 08:00 a.m. to 08:00 p.m.) and had free access
to food and water. The diet (Panlab, Barcelona, Spain)
consists of 54% carbohydrate, 17% protein, and 5% fat (the
residue was nondigestible material). The food intake was
measured daily. All animal manipulations were made in
accordance with the European Community guidelines for
the use of laboratory animals.
2.2 Tumor inoculation and treatment
Mice received an intramuscular (hind leg) inoculum of
5×105 Lewis lung carcinoma cells obtained from exponential
tumors. The Lewis lung carcinoma is a highly cachectic
rapidly growing mouse tumor containing poorly differentiated
cells, with a relatively short doubling time [27]. The animals
were divided into three groups: control (C), tumor-bearing
mice (TB), and tumor-bearing mice treated with the soluble
receptor antagonist of myostatin (sActRIIB) [22] at the dose
of 10 mg/kg s.c. twice a week (Fig. 1). sActRIIB sequesters
Activin A and Myostatin in vivo [22]. At day 14, after tumor
transplantation, the animals were weighed and anesthesized
with a ketamine/xylacine mixture (i.p.) (Imalgene® and
Rompun® respectively). The tumor was harvested from the
hind leg, its volume and mass evaluated, and number of lung
metastasis evaluated under the microscope. The metastases
weight was evaluated according to the methodology used by
Donati et al. [28]. Tissues were rapidly excised, weighed,
and frozen in liquid nitrogen.
2.3 Real-time polymerase chain reaction
Total RNA from tibialis muscle was extracted by
TriPureTM kit (Roche, Barcelona, Spain), a commercial
modification of the acid guanidinium isothiocyanate/
phenol/chloroform method [29]. First-strand cDNA was
synthesized from total RNA with oligo dT15 primers and
random primers pdN6 by using a cDNA synthesis kit
(Transcriptor Reverse Transcriptase, Roche, Barcelona,
Spain). Analysis of mRNA levels for the genes from the
different proteolytic systems was performed with primers
designed to detect the following gene products: ubiquitin
(FORWARD 5′ GAT CCA GGA CAA GGA GGG C 3′,
REVERSE 5′ CAT CTT CCA GCT GCT TGC CT3′); E2
(FORWARD: 5′ AGG CGA AGA TGG CGG T 3′;
REVERSE 5′ TCA TGC CTG TCC ACC TTG TA 3′);
C8 proteasome subunit (FORWARD 5′ AGA CCC CAA
CAT GAA ACT GC 3′; REVERSE 5′ AGG TTT GTT
GGC AGA TGC TC 3′); MuRF-1 (FORWARD 5′ TGT
CTG GAG GTC GTT TCC G 3′; REVERSE 5′ ATG CCG
GTC CAT GAT CAC TT 3′); Atrogin-1(FORWARD 5′
Fig. 1 Experimental protocol
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CCA TCA GGA GAA GTG GAT CTA TGT T 3′;
REVERSE 5′ GCT TCC CCC AAA GTG CAG TA 3′);
m-calpain (FORWARD 5′ TTG AGC TGC AGA CCA TC
3′; REVERSE 5′ GCA GCT TGA AAC CTG CTT CT 3′),
cathepsin B (FORWARD 5′ CTG CTGAGGACC TGC TTA
C 3′; REVERSE 5′ CAC AGG GAG GGA TGG TGT A3′)
and p0 (FORWARD 5′ GAG GTC CTC CTT GGT GAA CA
3′; REVERSE 5′CCTCATTGTGGGAGCAGACA 3′). To
avoid the detection of possible contamination by genomic
DNA, primers were designed in different exons. The real-time
polymerase chain reaction (PCR) was performed using a
commercial kit (LightCycler TM FastStart DNA MasterPLUS
SYBR Green I, Roche, Barcelona, Spain). The relative
amount of all mRNA was calculated using comparative CT
method. Acidic ribosomal phosphoprotein P0 mRNA was
used as the invariant control for all studies.
2.4 Total physical activity
Total physical activity (IR ACTIMETER System and
ACTITRAK software from Panlab, Barcelona) was
determined during the last 24 h before the sacrifice of the
animals in a two subgroups of four TB mice (non-treated) and
four TB mice (treated with the sActRIIB) using activity
sensors that translate individual changes in the infrared pattern
caused by movements of the animals into arbitrary activity
counts. For the measurements, animals remained in their
home cage. A frame containing an infrared beam system was
placed on the outside of the cage; this minimized stress to the
animals.
2.5 Grip force assessment
Skeletal muscular strength in mice was quantified by the
grip strength test [30, 31]. The grip strength device (Panlab-
Harvard Apparatus, Spain) comprised a triangular pull bar
connected to an isometric force transducer (dynamometer).
Basically, the grip strength meter was positioned horizon-
tally and the mice are held by the tail and lowered towards
the device. The animals are allowed to grasp the triangular
pull bar and were then pulled backwards in the horizontal
plane. The force applied to the bar just before it lost grip
was recorded as the peak tension. At least three measure-
ments were taken per mouse on both baseline and test days,
and the results were averaged for analysis. This force was
measured in grams/gram initial body weight.
2.6 Statistical analysis
Statistical analysis of the data was performed by means of
one-way and two-way analysis of variance.
3 Results and discussion
The mouse Lewis lung carcinoma is a suitable model system
to study the mechanisms involved in the establishment of
Table 1 Effects of sActRIIB treatment on body weights and food intake in mice bearing the Lewis lung carcinoma
C T T+A ANOVA
A B
Initial body weight (g) 19.4±0.3 19.3±0.2 19.2±0.4 ns ns
Final body weight (g) 19.8±0.3 17.7±0.2 21.0±0.6 0.0032 0.0000
Body weight increase (%) −8.20% 9.30%
Carcass 77±2 57±0.7 70±2.1 0.0000 0.0000
Total food intake 13.5±0.2 11.8±0.2 13.0±0.4 0.0008 0.0053
Results are mean±S.E.M. Food intake is expressed in g/100 g of initial body weight and refers to the ingestion during the period of the experiment
prior to sacrifice which took place 14 days after tumor inoculation. Final body weight excludes the tumor weight. Carcass (body without organs or
tumor) is expressed as g/100 g of initial body weight (IBW). Statistical significance of the results by two-way analysis of variance (ANOVA)
C control mice (n=6), T tumor-bearing mice (n=8), T+A tumor-bearing mice treated with sActRIIB (n=8), ns nonsignificant differences, A
(tumor effect), B (treatment effect)
Table 2 Effects of sActRIIB treatment on muscle weights in mice
bearing the Lewis lung carcinoma
C T T+A ANOVA
A B
Gastrocnemius 581±11 446±9 587±15 0.0000 0.0000
Tibialis 174±5 130±4 177±7 0.0000 0.0000
EDL 84±3 25±3 31±3 0.0000 ns
Soleus 54±5 23±2 28±2 0.0000 ns
Results are mean±S.E.M. Muscle weights are expressed as mg/100 g
of initial body weight. Statistical significance of the results by two-
way analysis of variance (ANOVA)
EDL extensor digitorum longus, C control mice (n=6), T tumor-bearing
mice (n=8), T+A tumor-bearing mice treated with sActRIIB (n=8), ns
nonsignificant differences, A (tumor effect), B (treatment effect)
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cachexia. This tumor has been described as an anaplastic
epidermoid with a marked haemorrhagic tendency, which
produces multiple lung metastasis and is extremely refractory
to most chemotherapeutic agents [32]. It is a well-known
neoplasia that because of its fast growth rate and lung
metastatic potential quickly causes death [27]. The
growth of the Lewis lung carcinoma causes a rapid and
progressive loss of body weight and tissue wasting,
particularly in skeletal muscle [33]. Different therapeutic
approaches have lead to positive results in neutralizing
muscle wasting in this experimental model [34, 35], and
recently a new strategy has been developed: to specifically
block myostatin pathway [22].
As can be seen in Table 1, administration of sActRIIB
resulted in an improvement in final body weight, the body
weight increase being around 9%, while in untreated
animals, the loss of weight was around 8%. This increase
in body weight resulted also in an increase in carcass
weight (mainly muscle and bone). Interestingly, sActRIIB
treatment also resulted in an increase in food intake.
Moreover, the increase in body weight affected individual
muscle weights. Thus, as can be seen in Table 2,
sActRIIB treatment resulted in a significant increase in
gastrocnemius and tibialis muscles (31% and 36%,
respectively). In fact, similar results has recently been
published using the sActRIIB administration strategy in
another mouse tumor model [22]. The authors concluded
that in addition of an amelioration of muscle weight,
treatment with the myostatin antagonist leads to prolonged
survival [22]. In the rest of muscles analyzed (EDL and
soleus), a clear tendency for bigger muscles as a result of
treatment was observed; however, the differences did not
reach statistical significance. Treatment slightly decreases
the tumor weight and its volume, although it did not
influence the metastatic lung area or the volume of the
metastasis (Table 3).
Bearing in mind, the effects of the treatment on body
weight and particularly in individual muscle weights, a set
of experiments to measure physical performance were
carried out using a physical actimeter [36]. As can be seen
in Table 4, the implantation of the tumor resulted in a
decrease of total physical activity (75%), mean velocity
Table 3 Effects of sActRIIB treatment on tumor mass and metastases
in mice bearing the Lewis lung carcinoma
T T+A ANOVA
Tumor weight (mg) 4,354±213 3,790±153 0.0497
Tumor volume (ml) 5.0±0.33 4.2±0.2 0.0492
Metastases number 6.2±1.1 3.6±0.8 ns
Metastases volume 29.9±13.3 28.7±11 ns
% Lung metastases 15.7±6.7 19.9±7.5 ns
Results are mean±S.E.M. for eight animals. Statistically significant
difference by post hoc Duncan test. Statistical significance of the
results by one-way analysis of variance (ANOVA), treatment effect
T tumor-bearing mice, T+A tumor-bearing mice treated with
sActRIIB, ns nonsignificant differences
Table 4 Last 24 h of physical activity in mice bearing the Lewis lung carcinoma treated with sActRIIB
C T T+A ANOVA
A B
Physical activity
Total physical activity 56,401±531 14,118±2,633 12,395±1,199 0.0000 ns
Stereotyped movements 4,005±876 1,245±387 1,517±330 0.0087 ns
Locomotor movements 52,396±1,373 12,874±2,615 10,878±1,240 0.0000 ns
Mean velocity 0.32±0.04 0.06±0.01 0.09±0.02 0.0000 ns
Total traveled distance 27,455±3,316 5,603±599 7,979±1,234 0.0000 ns
Time
Resting time (%) 86.9±0.5 95.7±0.5 91±1.8 0.0009 0.0292
Slow-movements time (%) 9.4±0.7 4.0±0.6 8.6±1.7 0.0074 0.0173
Fast-movements time (%) 3.6±0.66 0.3±0.03 0.4±0.12 0.0002 ns
Physical activity is expressed in activity units. Stereotyped movements include movements without displacement (eating and cleaning
movements); conversely, locomotor movements include movements with displacement. Mean velocity is expressed in centimeters per second.
Traveled distance is expressed in centimeters. Time is expressed as percentage of total time (24 h). The thresholds of time are the following: time
involving resting (sleeping, cleaning, and eating time): [0–2] cm/s, time involving slow movements: [2–5] cm/s and time involving fast
movements: [>5] cm/s. Results are mean±S.E.M. for four animals. Statistical significance of the results by two-way analysis of variance
(ANOVA)
C control mice, T tumor-bearing mice, T+A tumor-bearing mice treated with sActRIIB, ns nonsignificant differences, A (tumor effect), B
(treatment effect)
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(81%), and total traveled distance (80%). Resting time was
increased and the time involved in different types of
movements was decreased. Similar results from our
laboratory have been obtained in another tumor model
[36]. As a result of the sActRIIB treatment, there was a
decrease in the resting time percentage and an increase in
the period of time related with slow movements (Table 4).
These data suggest that sActRIIB treatment caused a slight
improvement in physical performance.
In order to see if the increase of muscle weight and
physical performance was related with increased muscle
performance, grip force was determined using a specialized
device dynamometer. The results presented in Table 5
clearly show an increase in muscle force as a result of
sActRIIB treatment.
Finally, and since muscle wasting during cancer has been
related with the activity of different proteolytic systems
involved in enhanced muscle protein breakdown during
catabolic conditions [5, 34, 37, 38], the mRNA expression
levels of different genes related to proteolysis was
measured following sActRIIB treatment. Indeed, tumor
burden resulted in generalized increases in the majority of
the components of the ubiquitin-dependent proteolytic
system analyzed. An increase in m-Calpain (calcium-
dependent system) and Cathepsin B (lysosomal system)
were also observed in the tibialis muscle of the tumor-
bearing animals (Table 6). Surprisingly, sActRIIB treatment
did not influence the mRNA expression levels of the
different components of the ubiquitin-dependent proteolytic
system. However, sActRIIB treatment significantly
decreases both calcium-dependent and lysosomal markers
(Table 6). PCR real-time analysis of tibialis muscle revealed
that tumor-bearing mice myostatin expression increased
1.5-fold over non-tumor bearing mice and that tumor-
bearing mice treated with sActRIIB expressed similar levels
of myostatin as found in non-treated tumor-bearing mice
(Table 6).
It has to be pointed out that the calpain system could
well play an important role in muscle proteolysis during
cancer. From this point of view, Costelli et al. have reported
an important role of calcium-dependent proteolysis both in
animals [39] and humans [40]. In addition, Hasselgren et al.
Table 5 Effects of sActRIIB treatment on muscle force in mice
bearing the Lewis lung carcinoma
C T T+A
Grip force (day 0) 5.1±0.21a,c 4.7±0.20a,c 5.2±0.24a,c
Grip force (day 14) 5.0±0.23a,c 2.8±0.16b,d 4.4±0.3a,c
Grip force is expressed as grams per gram IBW. Results are mean±S.
E.M. Statistical significance of the results by one-way analysis of
variance (ANOVA). Statistically significant difference by post hoc
Duncan test. Different letters in superscript indicate significant
differences between groups (a and b: differences between C, T, and
T+A groups the same day of measurement; and c and d: differences
between days 0 and 14 in the same group)
C control mice (n=4), T tumor-bearing mice (n=8), T+A tumor-bearing
mice treated with sActRIIB (n=8)
Table 6 Effects of sActRIIB treatment on tibialis muscle mRNA content of the different proteolytic systems and myostatin in mice bearing the
Lewis lung carcinoma




Ubiquitin 100±5 159±9 152±9 0.0001 ns
C8 proteasome subunit 100±5 159±8 144±8 0.0000 ns
MuRF-1 100±24 207±15 206±49 0.0116 ns
Atrogin-1 100±24 266±21 250±36 0.0001 ns
E2 100±5 115±5 108±6 ns ns
Calcium-dependent
m-Calpain 100±7 146±6 107±5 0.0001 0.0004
Lysosomal
Cathepsin B 100±6 126±7 90±8 0.0430 0.0040
Myostatin 100±5 159±9 152±9 0.0158 ns
Results are mean±S.E.M. for four to eight animals. The results are expressed as a percentage of controls. Statistical significance of the results by
two-way analysis of variance (ANOVA)
C control animals, T tumor-bearing mice, T+A tumor-bearing mice treated with sActRIIB, ns nonsignificant differences, A (tumor effect), B
(treatment effect)
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have attributed a key role to calpains in the early stages of
muscle protein degradation [41]. Indeed, the calcium-
dependent proteases participate in the release of the
myofilaments from the sarcomere; these myofilaments
would later be degraded by the ubiquitin-dependent
proteolytic system [41]. Very recently, a role for lysosome
activity in muscle degradation during cancer cachexia has
been also pointed out. Indeed, activation of FoxO3
stimulates lysosomal proteolysis in muscle by activating
autophagic-related genes [42]. It is well-known that FoxO3
is one of the main transcription factors involved in the
activation of atrogenes, a family of genes responsible for
triggering atrophy in skeletal muscle [43].
From the results presented here, it can be concluded that
exploring the inhibition of the myostatin system could well
be an optimal strategy, particularly in combination with a
nutritional approach, for the amelioration of a cachectic
syndrome in humans.
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